

al

Appl. No.: 08/443184






FIG. 2

Appl. No.: 08/443184






FIG. 3






FIG. 4






FIG. 5

al.

Appl. No.: 08/443184






FIG. 6






FIG. 7



PURIFICATION SCHEME




FIG. 8


al.

Appl. No.: 08/443184



TOT AVAILABLE COPY

WESTERN BLOT (UNDER NON-REDUCING CONDITIONS)



LANE	SAMPLE
1.	hfib, 100 ngs
2.	TG 1-11-4 (pellet-2), 15 ngs
3.	TG 1-11-4 (pellet-2), 15 ngs
4.	TG 1-6-9 (pellet-2), 30 ngs
5.	TG 1-6-9 (pellet-2), 30 ngs
6.	DIAFILTERED MOUSE PLASMA, 1-2 µgs
7.	NTG (pellet-2), 600 ngs
8.	hfib, 10 ngs

FIG. 9

al.

Appl. No.: 08/443184



REST AVAILABLE COPY

WESTERN BLOT (SDS-PAGE UNDER REDUCING CONDITIONS)

1	2	3	4	5	6	7	8
					•	1	-
	2					A.	

LANE	SAMPLE
1.	HUMAN FIBRINOGEN (100 ngs)
2.	hFib (50 ngs)
3.	hFib (10 ngs)
4.	MOUSE PLASMA DERIVATIVE (200 ngs)
5.	TG WHEY (pellet-2) 60 ngs
6.	TG WHEY (pellet-2) 30 ngs
7.	TG WHEY (pellet-2) 15 ngs
8.	TG WHEY (pellet-2) 8 ngs

FIG. 10


Appl. No.: 08/443184



BEST AVAILABLE COPY

ANALYSIS OF PRODUCTS UNDER REDUCING CONDITIONS THROMBIN ASSISTED CLOT FORMATION

1 2 3 4 5 6 7



LANE	SAMPLE
1.	hFib (50 ngs)-BEFORE THROMBIN
2.	hFib (10 ngs)-BEFORE THROMBIN
3.	hFib (10 ngs)-RESUSPENDED CLOT
4.	TG WHEY (pellet-2) 30 ngs-BEFORE THROMBIN
5.	TG WHEY (pellet-2)-RESUSPENDED CLOT
6.	MOUSE PLASMA DERIVATIVE 1000 ngs-BEFORE THROMBIN
7.	MOUSE PLASMA DERIVATIVE 1000 ngs-RESUSPENDED

FIG. 11